CHU Gui de Chauliac
- Address
- lock Available on a paid plan
CHU Gui de Chauliac - Neurodegenerative Disease Research
CHU Gui de Chauliac is a prominent academic medical center engaged in advanced clinical research for neurodegenerative disorders. The center specializes in conducting large-scale, multicenter trials focused on developing innovative therapeutic approaches for progressive neurological conditions, with particular emphasis on combination therapy strategies.
- Amyotrophic Lateral Sclerosis (ALS) treatment optimization
- Novel tyrosine kinase inhibitor therapies in combination with established treatments
- Phase 3 clinical trials for neurodegenerative disease interventions
The center's research portfolio includes rigorous double-blind, placebo-controlled studies evaluating the efficacy and safety of emerging pharmacological agents as add-on therapies. Their work in ALS research focuses on assessing combination treatments with Riluzole, exploring how targeted molecular therapies such as masitinib may enhance outcomes for patients suffering from this devastating motor neuron disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Ab Science1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Gui de Chauliac
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Masitinib Plus Riluzole Versus Placebo Plus Riluzole in Amyotrophic Lateral Sclerosis: A Phase 3 Randomized Controlled Trial | Ab Science | Phase III | Not Yet Recruiting | May 2021 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Masitinib | 1 | Unknown | 2021-05-24 | 2021-05-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.